OptimizeRx (OPRX) News Today $5.15 -0.07 (-1.34%) (As of 11/1/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Rice Hall James & Associates LLC Acquires 119,306 Shares of OptimizeRx Co. (NASDAQ:OPRX)Rice Hall James & Associates LLC raised its holdings in OptimizeRx Co. (NASDAQ:OPRX - Free Report) by 24.0% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 615,441 shares of the company's stock after acquiring an additional 119,306November 1 at 7:34 AM | marketbeat.comOptimizeRx Sets Third Quarter 2024 Conference Call for November 13, 2024 at 4:30 p.m. ETOctober 31 at 7:30 AM | globenewswire.comOptimizeRx Co. (NASDAQ:OPRX) Shares Bought by Renaissance Technologies LLCRenaissance Technologies LLC raised its stake in shares of OptimizeRx Co. (NASDAQ:OPRX - Free Report) by 101.8% in the second quarter, according to its most recent 13F filing with the SEC. The fund owned 142,146 shares of the company's stock after buying an additional 71,700 shares during the perioOctober 5, 2024 | marketbeat.comFirst Light Asset Management LLC Purchases 89,377 Shares of OptimizeRx Co. (NASDAQ:OPRX)First Light Asset Management LLC increased its position in shares of OptimizeRx Co. (NASDAQ:OPRX - Free Report) by 5.1% during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,826,961 shares of the company's stock after acSeptember 24, 2024 | marketbeat.comOptimizeRx Co. (NASDAQ:OPRX) Shares Sold by Blair William & Co. ILBlair William & Co. IL reduced its holdings in OptimizeRx Co. (NASDAQ:OPRX - Free Report) by 17.7% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 643,757 shares of the company's stock after selling 138,816 shares during the quSeptember 21, 2024 | marketbeat.comDivisadero Street Capital Management LP Lowers Stake in OptimizeRx Co. (NASDAQ:OPRX)Divisadero Street Capital Management LP lessened its stake in OptimizeRx Co. (NASDAQ:OPRX - Free Report) by 16.3% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,315,913 shares of the company's stock after selling 256,9September 20, 2024 | marketbeat.comOptimizeRx: A Strong Buy on Client Commitments and Growth PotentialSeptember 11, 2024 | markets.businessinsider.comRice Hall James & Associates LLC Has $4.96 Million Holdings in OptimizeRx Co. (NASDAQ:OPRX)Rice Hall James & Associates LLC increased its position in shares of OptimizeRx Co. (NASDAQ:OPRX - Free Report) by 23.5% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 496,135 shares of the company's stock after purchasSeptember 11, 2024 | marketbeat.comOptimizeRx Continues to Expand its Strategic Relationship with a Top-Tier Pharma Client via a Multi-Brand, Multi-Solution Investment Commitment with Over $10M In-Year Total ValueSeptember 10, 2024 | globenewswire.comOptimizeRx Launches Novel Brand Eligibility Technology, Enabling Dynamic Direct to Consumer Marketing for Healthcare AudiencesSeptember 9, 2024 | globenewswire.comOptimizeRx (NASDAQ:OPRX) PT Lowered to $14.00 at Royal Bank of CanadaRoyal Bank of Canada decreased their price target on shares of OptimizeRx from $17.00 to $14.00 and set an "outperform" rating for the company in a research report on Friday.August 16, 2024 | marketbeat.comOptimizeRx Second Quarter 2024 Earnings: EPS Beats Expectations, Revenues LagAugust 12, 2024 | finance.yahoo.comOptimizeRx (NASDAQ:OPRX) PT Lowered to $11.00Barclays reduced their target price on shares of OptimizeRx from $15.00 to $11.00 and set an "equal weight" rating for the company in a report on Monday.August 12, 2024 | marketbeat.comEarnings Release: Here's Why Analysts Cut Their OptimizeRx Corporation (NASDAQ:OPRX) Price Target To US$15.79August 11, 2024 | finance.yahoo.comOptimizeRx Corporation (OPRX) Q2 2024 Earnings Call TranscriptAugust 9, 2024 | seekingalpha.comOptimizeRx Maintains Buy Rating: Robust Sales Pipeline and Improved Operational Efficiency Signal Strong Future GrowthAugust 9, 2024 | markets.businessinsider.comOptimizeRx Corporation (NASDAQ:OPRX) Q2 2024 Earnings Call TranscriptAugust 9, 2024 | msn.comOPRX Stock Earnings: OptimizeRx Beats EPS, Misses Revenue for Q2 2024August 8, 2024 | investorplace.comInstitutional investors may adopt severe steps after OptimizeRx Corporation's (NASDAQ:OPRX) latest 24% drop adds to a year lossesAugust 8, 2024 | finance.yahoo.comOptimizeRx Corporation (OPRX)August 6, 2024 | finance.yahoo.comOptimizeRx (OPRX) Set to Announce Quarterly Earnings on ThursdayOptimizeRx (NASDAQ:OPRX) will be releasing earnings after the market closes on Thursday, August 8, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=612881)August 1, 2024 | marketbeat.comQ3 2024 Earnings Estimate for OptimizeRx Co. (NASDAQ:OPRX) Issued By B. RileyOptimizeRx Co. (NASDAQ:OPRX - Free Report) - Research analysts at B. Riley issued their Q3 2024 EPS estimates for OptimizeRx in a research note issued to investors on Wednesday, July 24th. B. Riley analyst K. Bauser anticipates that the company will post earnings of ($0.16) per share for the quarJuly 29, 2024 | marketbeat.comEquities Analysts Issue Forecasts for OptimizeRx Co.'s Q2 2024 Earnings (NASDAQ:OPRX)OptimizeRx Co. (NASDAQ:OPRX - Free Report) - B. Riley issued their Q2 2024 earnings estimates for shares of OptimizeRx in a research report issued on Wednesday, July 24th. B. Riley analyst K. Bauser expects that the company will earn ($0.26) per share for the quarter. B. Riley has a "Buy" ratingJuly 26, 2024 | marketbeat.comOptimizeRx (NASDAQ:OPRX) Research Coverage Started at B. RileyB. Riley started coverage on OptimizeRx in a research note on Thursday. They issued a "buy" rating and a $18.50 price objective on the stock.July 25, 2024 | marketbeat.comOptimizeRx Sets Second Quarter 2024 Conference Call for August 8, 2024 at 4:30 p.m. ETJuly 25, 2024 | globenewswire.comOptimizeRx Delivers AI-Guided Privacy-Compliant Platform for Pharmaceutical Brand Marketing Amid Evolving Consumer Privacy LegislationJuly 23, 2024 | globenewswire.comOptimizeRx Co. (NASDAQ:OPRX) Receives Average Recommendation of "Moderate Buy" from AnalystsShares of OptimizeRx Co. (NASDAQ:OPRX - Get Free Report) have received an average recommendation of "Moderate Buy" from the seven analysts that are covering the firm, Marketbeat reports. One analyst has rated the stock with a hold recommendation and six have issued a buy recommendation on the coJuly 21, 2024 | marketbeat.comOptimizeRx Demonstrates Measurable Script Lift for a Major Depressive Disorder Brand Targeting Physicians of Hard-to-Reach PatientsJuly 15, 2024 | globenewswire.comEssex Investment Management Co. LLC Purchases New Stake in OptimizeRx Co. (NASDAQ:OPRX)Essex Investment Management Co. LLC bought a new stake in OptimizeRx Co. (NASDAQ:OPRX - Free Report) during the 1st quarter, according to its most recent Form 13F filing with the SEC. The firm bought 86,656 shares of the company's stock, valued at approximately $1,053,000. Essex Investment ManagemeJuly 11, 2024 | marketbeat.comJMP Securities Reiterates Market Outperform Rating for OptimizeRx (NASDAQ:OPRX)JMP Securities reaffirmed a "market outperform" rating and issued a $16.00 price objective on shares of OptimizeRx in a research note on Friday.June 21, 2024 | marketbeat.comNew White Paper Highlights How Closing the Health Information Gap Between Doctors and Patients Improves Life Science Marketing & Adds Value to Clinical ConversationsJune 20, 2024 | globenewswire.comOptimizeRx Co. (NASDAQ:OPRX) Shares Acquired by G2 Investment Partners Management LLCG2 Investment Partners Management LLC boosted its position in OptimizeRx Co. (NASDAQ:OPRX - Free Report) by 26.0% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 468,120 shares of the company's stock after purchasing an additional 96,646 shareJune 13, 2024 | marketbeat.comFirst Light Asset Management LLC Lowers Holdings in OptimizeRx Co. (NASDAQ:OPRX)First Light Asset Management LLC decreased its position in OptimizeRx Co. (NASDAQ:OPRX - Free Report) by 30.5% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 1,727,298 shares of the company's stock after selling 758,749 shares during the period. OptJune 12, 2024 | marketbeat.comAvenir Corp Has $1.26 Million Stock Holdings in OptimizeRx Co. (NASDAQ:OPRX)Avenir Corp trimmed its position in OptimizeRx Co. (NASDAQ:OPRX - Free Report) by 71.3% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 88,260 shares of the company's stock after sJune 11, 2024 | marketbeat.comOptimizeRx Co. (NASDAQ:OPRX) Given Average Recommendation of "Moderate Buy" by BrokeragesShares of OptimizeRx Co. (NASDAQ:OPRX - Get Free Report) have earned an average rating of "Moderate Buy" from the seven brokerages that are covering the firm, MarketBeat.com reports. One analyst has rated the stock with a hold rating and six have given a buy rating to the company. The average 12-June 1, 2024 | marketbeat.comMillrace Asset Group Inc. Purchases Shares of 133,936 OptimizeRx Co. (NASDAQ:OPRX)Millrace Asset Group Inc. purchased a new stake in OptimizeRx Co. (NASDAQ:OPRX - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 133,936 shares of the company's stock, valued aMay 27, 2024 | marketbeat.comOptimizeRx Corporation: OptimizeRx Reports First Quarter 2024 Financial ResultsMay 15, 2024 | finanznachrichten.deOptimizeRx Shares Rise 23% on 1Q Revenue Beat, FY GuidanceMay 15, 2024 | marketwatch.comStifel Nicolaus Reaffirms Their Buy Rating on OptimizeRx (OPRX)May 15, 2024 | markets.businessinsider.comOptimizeRx Corporation (NASDAQ:OPRX) Q1 2024 Earnings Call TranscriptMay 15, 2024 | msn.comOptimizeRx (NASDAQ:OPRX) PT Raised to $16.00 at JMP SecuritiesJMP Securities boosted their price target on OptimizeRx from $15.00 to $16.00 and gave the company a "market outperform" rating in a research report on Wednesday.May 15, 2024 | marketbeat.comOptimizeRx (NASDAQ:OPRX) Issues Quarterly Earnings Results, Misses Estimates By $0.16 EPSOptimizeRx (NASDAQ:OPRX - Get Free Report) issued its earnings results on Tuesday. The company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.16). The firm had revenue of $19.69 million during the quarter, compared to analysts' expectations of $18.66 million. OptimizeRx had a negative return on equity of 7.72% and a negative net margin of 24.56%. During the same period last year, the firm posted ($0.34) earnings per share.May 15, 2024 | marketbeat.comStifel Nicolaus Reiterates Buy Rating for OptimizeRx (NASDAQ:OPRX)Stifel Nicolaus reiterated a "buy" rating and set a $13.00 price objective on shares of OptimizeRx in a report on Wednesday.May 15, 2024 | marketbeat.comOptimizeRx Corp (OPRX) Q1 2024 Earnings Call Transcript Highlights: Surging Revenues and ...May 15, 2024 | finance.yahoo.comOPRX Stock Earnings: OptimizeRx Beats EPS, Beats Revenue for Q1 2024May 14, 2024 | investorplace.comOptimizeRx Reports First Quarter 2024 Financial ResultsMay 14, 2024 | globenewswire.comOptimizeRx (OPRX) Set to Announce Earnings on TuesdayOptimizeRx (NASDAQ:OPRX) will be releasing earnings after the market closes on Tuesday, May 14, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=590375)May 7, 2024 | marketbeat.comOptimizeRx to Participate in Upcoming Investor ConferencesMay 6, 2024 | globenewswire.comBuy Rating Reaffirmed for AbbVie: Future Growth Beyond Humira’s CompetitionApril 29, 2024 | markets.businessinsider.comFederated Hermes Inc. Has $2.62 Million Holdings in OptimizeRx Co. (NASDAQ:OPRX)Federated Hermes Inc. lowered its position in shares of OptimizeRx Co. (NASDAQ:OPRX - Free Report) by 47.3% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 182,985 shares of the company's stock after selling 1April 28, 2024 | marketbeat.com Get OptimizeRx News Delivered to You Automatically Sign up to receive the latest news and ratings for OPRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Crypto Crash Ahead? (27 Experts Weigh In) (Ad)Your Portfolio Could Be at RISK Emergency summit reveals crypto could save you! Click here to reserve your spot at the emergency crypto summit now. OPRX Media Mentions By Week OPRX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. OPRX News Sentiment▼0.770.42▲Average Computer and Technology News Sentiment OPRX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. OPRX Articles This Week▼22▲OPRX Articles Average Week Get OptimizeRx News Delivered to You Automatically Sign up to receive the latest news and ratings for OPRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies TELUS International (Cda) News MaxCyte News Bowman Consulting Group News Ooma News IBEX News Spree Acquisition Corp. 1 News Resources Connection News Accolade News 8X8 News CPI Card Group News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:OPRX) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Elon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…Crypto 101 Media | Sponsored[Just Released] Jovine's Emergency Briefing insidePeople didn't believe Jovine when he predicted the 2008 financial crisis over a year in advance. But some read...Behind the Markets | SponsoredHe made 1,303,329 in 12 months after Biden won…Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… ...Timothy Sykes | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding OptimizeRx Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share OptimizeRx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
